“We are elated to have the support of the Distinguished Scientist Award to explore ambitious novel approaches to tackle brain cancers, and thrilled to join the Sontag community of pioneering researchers dedicated to advancing towards a cure for these devastating malignancies."
About DSA-Funded Research
Cancer evolution constitutes a foremost obstacle to effective treatment, driving malignant cells to adapt and overcome therapy. We hypothesize that both genetic and epigenetic determinants govern the biology of key cellular states that drive gliomas and their plasticity, calling for an integrative model of cancer evolution, encompassing both genetic and epigenetic sources of heritable variations within tumors. To address this challenge, the Landau laboratory developed novel multi-omics single-cell sequencing technologies that enable direct integration across genetic, epigenetic, and cell state dimensions of cell-to-cell variation, and have applied them to study clonal evolution in hematological malignancies. In this Sontag funded project, we seek to apply this multi-layered single-cell approach to human gliomas in order to define how cellular plasticity (i.e., the ability to switch between cell states) and evolution enable tumor cell growth.
Core member, New York Genome Center, NYC, NY
Assistant Professor of Medicine, Weill Cornell Medicine, Division of Hematology and Medical
Oncology, NYC, NY
Assistant Professor of Physiology and Biophysics, Weill Cornell Medicine, NYC, NY
Member, Institute of Computational Biomedicine, Weill Cornell Medicine, NYC, NY
Tel Aviv University, B.S.
Tel Aviv University, Sackler School of Medicine, M.D.
Paris Diderot University, Ph.D.
Yale New Haven Hospital, Internal Medicine Intern
Yale New Haven Hospital, Yale Cancer Center, Internal Medicine Resident
Yale Cancer Center, Hematology & Medical Oncology Fellow
DFCI/The Broad Institute/MIT, Postdoctoral Research Fellow